<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03136406</url>
  </required_header>
  <id_info>
    <org_study_id>QUILT-3.039</org_study_id>
    <nct_id>NCT03136406</nct_id>
  </id_info>
  <brief_title>QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy</brief_title>
  <official_title>NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunityBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunityBio, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination&#xD;
      therapy in subjects with pancreatic cancer who have progressed on or after previous Standard&#xD;
      of Care first line therapy and chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment will be administered in two phases. Subjects will continue treatment until they&#xD;
      experience progressive disease (PD) or experience unacceptable toxicity (not correctable with&#xD;
      dose reduction), withdraw consent, or the investigator feels it is no longer in the subject's&#xD;
      best interest to continue treatment. Those who have a complete response (CR) will enter phase&#xD;
      2 of the study. Subjects may remain on phase 2 of the study for up to 1 year. Treatment will&#xD;
      continue throughout phase 2 until the subject experiences PD or unacceptable toxicity,&#xD;
      withdraws consent, or the investigator feels it is no longer in the subject's best interest&#xD;
      to continue treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 14, 2017</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Phase 1b primary endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate by RECIST</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 primary endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate by irRC</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 primary endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate by RECIST</measure>
    <time_frame>8 weeks</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate by irRC</measure>
    <time_frame>8 weeks</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival by RECIST during Phase 1b</measure>
    <time_frame>8 weeks</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival by irRC during Phase 1b</measure>
    <time_frame>8 weeks</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>8 weeks</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes of pancreatic cancer symptoms</measure>
    <time_frame>8 weeks</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival by RECIST during Phase 2</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival by irRC during Phase 2</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (confirmed complete response, partial response, or stable disease lasting for at least 2 months).</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes of pancreatic cancer symptoms</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent AEs, SAEs, graded using the NCI CTCAE Version 4.03.</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A combination of agents will be administered to subjects in this study:&#xD;
cyclophosphamide, oxaliplatin, capecitabine, fluorouracil, leucovorin, nab-paclitaxel, bevacizumab, avelumab, ALT-803, aNK, GI-4000, and ETBX-011.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>5-fluoro-2,4 (1H,3H)-pyrimidinedione</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Recombinant human anti-VEGF IgG1 monoclonal</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>avelumab</intervention_name>
    <description>Recombinant human anti-PD-L1 IgG1 monoclonal antibody</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALT-803</intervention_name>
    <description>Recombinant human super agonist interleukin-15 (IL-15) complex</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aNK for Infusion</intervention_name>
    <description>NK-92 cells</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-011</intervention_name>
    <description>Ad5 [E1-, E2b-]-CEA</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-4000</intervention_name>
    <description>Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old.&#xD;
&#xD;
          -  Able to understand and provide a signed informed consent that fulfills the relevant&#xD;
             IRB or IEC guidelines.&#xD;
&#xD;
          -  Histologically-confirmed pancreatic cancer with progression on or after SoC therapy.&#xD;
&#xD;
          -  ECOG performance status of 0 to 2.&#xD;
&#xD;
          -  Have at least 1 measurable lesion and/or non-measurable disease evaluable according to&#xD;
             RECIST Version 1.1.&#xD;
&#xD;
          -  Must have a recent tumor biopsy specimen following the conclusion of the most recent&#xD;
             anti-cancer treatment. If a historic specimen is not available, the subject must be&#xD;
             willing to undergo a biopsy during the screening period.&#xD;
&#xD;
          -  Must be willing to provide blood samples for exploratory analyses.&#xD;
&#xD;
          -  Ability to attend required study visits and return for adequate follow-up, as required&#xD;
             by this protocol.&#xD;
&#xD;
          -  Agreement to practice effective contraception for female subjects with child-bearing&#xD;
             potential and non-sterile males.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of persistent grade 2 or higher (CTCAE Version 4.03) hematological toxicity&#xD;
             resulting from previous therapy.&#xD;
&#xD;
          -  History of other active malignancies or brain metastasis except: controlled basal cell&#xD;
             carcinoma; prior history of in situ cancer (eg, breast, melanoma, cervical); prior&#xD;
             history of prostate cancer that is not under active systemic treatment (except&#xD;
             hormonal therapy) and with undetectable prostate-specific antigen (PSA) (&lt; 0.2 ng/mL);&#xD;
             bulky (≥ 1.5 cm) disease with metastasis in the central hilar area of the chest and&#xD;
             involving the pulmonary vasculature. Subjects with a history of another malignancy&#xD;
             must have &gt; 5 years without evidence of disease.&#xD;
&#xD;
          -  Serious uncontrolled concomitant disease that would contraindicate the use of the&#xD;
             investigational drug used in this study or that would put the subject at high risk for&#xD;
             treatment-related complications.&#xD;
&#xD;
          -  Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's&#xD;
             disease, autoimmune disease associated with lymphoma).&#xD;
&#xD;
          -  History of organ transplant requiring immunosuppression.&#xD;
&#xD;
          -  History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative&#xD;
             colitis).&#xD;
&#xD;
          -  Requires whole blood transfusion to meet eligibility criteria.&#xD;
&#xD;
          -  Inadequate organ function, evidenced by the following laboratory results:&#xD;
&#xD;
               -  White blood cell (WBC) count &lt; 3,500 cells/mm3&#xD;
&#xD;
               -  Absolute neutrophil count &lt; 1,500 cells/mm3.&#xD;
&#xD;
               -  Platelet count &lt; 100,000 cells/mm3.&#xD;
&#xD;
               -  Hemoglobin &lt; 9 g/dL.&#xD;
&#xD;
               -  Total bilirubin greater than the upper limit of normal (ULN; unless the subject&#xD;
                  has documented Gilbert's syndrome).&#xD;
&#xD;
               -  Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT])&#xD;
                  &gt; 2.5 × ULN (&gt; 5 × ULN in subjects with liver metastases).&#xD;
&#xD;
               -  Alkaline phosphatase levels &gt; 2.5 × ULN (&gt; 5 × ULN in subjects with liver&#xD;
                  metastases, or &gt;10 × ULN in subjects with bone metastases).&#xD;
&#xD;
               -  Serum creatinine &gt; 2.0 mg/dL or 177 μmol/L.&#xD;
&#xD;
               -  International normalized ratio (INR) or activated partial thromboplastin time&#xD;
                  (aPTT) or partial thromboplastin time (PTT) &gt;1.5 × ULN (unless on therapeutic&#xD;
                  anti-coagulation).&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg) or&#xD;
             clinically significant (ie, active) cardiovascular disease, cerebrovascular&#xD;
             accident/stroke, or myocardial infarction within 6 months prior to first study&#xD;
             medication; unstable angina; congestive heart failure of New York Heart Association&#xD;
             grade 2 or higher; or serious cardiac arrhythmia requiring medication.&#xD;
&#xD;
          -  Dyspnea at rest due to complications of advanced malignancy or other disease requiring&#xD;
             continuous oxygen therapy.&#xD;
&#xD;
          -  Positive results of screening test for human immunodeficiency virus (HIV), hepatitis B&#xD;
             virus (HBV), or hepatitis C virus (HCV).&#xD;
&#xD;
          -  Current chronic daily treatment (continuous for &gt; 3 months) with systemic&#xD;
             corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone),&#xD;
             excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic&#xD;
             reaction or anaphylaxis in subjects who have known contrast allergies is allowed.&#xD;
&#xD;
          -  Known hypersensitivity to any component of the study medication(s).&#xD;
&#xD;
          -  Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug&#xD;
             reaction with any of the study medications. See Excluded Medications list.&#xD;
&#xD;
          -  Participation in an investigational drug study or history of receiving any&#xD;
             investigational treatment within 14 days prior to screening for this study, except for&#xD;
             testosterone-lowering therapy in men with prostate cancer.&#xD;
&#xD;
          -  Assessed by the investigator to be unable or unwilling to comply with the requirements&#xD;
             of the protocol.&#xD;
&#xD;
          -  Concurrent participation in any interventional clinical trial.&#xD;
&#xD;
          -  Pregnant and nursing women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chan Soon-Shiong Institute for Medicine</name>
      <address>
        <city>El Segundo</city>
        <state>California</state>
        <zip>90245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 19, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

